Viking Therapeutics announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

The stock has risen about 256% in 2024. Let's look at the latest trial results from Viking Therapeutics to see if it's a smart buy now despite already soaring this year. It's hard to overstate the ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

AstraZeneca PLC shed GBP15 billion of market capitalization on Tuesday, after investors were underwhelmed by early data from a trial of a weight-loss pill. The company (UK:AZN) said its lead product ...

At mid-session, the blue chip Dow Jones Industrial Average was up more than 400 points, or 1%, at 42,199. The broader S&P 500 ...

Sherwin-Williams (SHW) is up more than +4% after S&P Dow Jones Indices said the stock will replace Dow in the Dow Jones Industrial average before the start of trading on November 8. Viking ...

Conference call with CEO Dr. Lian and CFO Zante to be held on November 5 at 11:30 am hosted by JPMorgan. Webcast Link Published first on ...

Oppenheimer analyst Jay Olson maintained a Buy rating on Cognition Therapeutics (CGTX – Research Report) yesterday and set a price target ...

Dollar Tree (DLTR) faces CEO transition and market uncertainty as analysts weigh in on strategic measures and potential ...

Japanese gynecological benign tumor market is thriving with cutting-edge diagnostic technologies and minimally invasive ...

Vertex Pharmaceuticals beat Wall Street's third-quarter expectations, but the real story for Vertex stock is still to come, analysts said Tuesday.Please watch the video at Investors.com - How To Buy ...